Abstract 71P
Background
Ovarian cancer is the most common cause of death from gynecological malignancies. In the early stages, women are generally asymptomatic or have non-specific symptoms, making early-stage ovarian cancer undiagnosed. The different investigations reported the effect of polymorphisms in folate metabolism genes on ovarian cancer risk in different ethnicities. The aim of the current study was to analyze associations between the polymorphisms of key folate metabolism enzyme genes, methylene tetrahydrofolate reductase (MTHFR) and 5,10-methylenetetrahydrofolate dehydrogenase (MTHFD1) (C677T and G1958A, respectively) and ovarian cancer risk in Georgia. In addition, we assessed DNA methylation levels in ovarian cancer patients with polymorphic variants of these genes.
Methods
30 cancer patients and 30 healthy controls were included in this study. All patients and controls provided informed consent before being enrolled in the study. This study was approved by the Ethics Committee of the Tbilisi State Medical University. Genomic DNA was isolated from peripheral blood using a commercial kit (Qiagen, USA). Single Nucleotide Polymorphism (SNP) genotyping was performed using TaqMan Assay (Thermo Scientific, USA). Global DNA methylation was analyzed using the Global DNA Methylation Assay Kit (Abcam, MA, USA).
Results
The results suggest that there was a high association between MTHFD1 gene G1958A variant and the risk of ovarian cancer in Georgian patients (p<0.001). No statistically significant differences in allele and genotype frequencies of MTHFR gene C677T SNP were observed between patients and controls (p > 0.05). In addition, global DNA methylation in individuals with CT+TT genotypes were found to be reduced compared to CC genotypes in respect to the C677T variant of MTHFR gene.
Conclusions
In our study, we did not find any association between the MTHFR gene C677T polymorphism and ovarian cancer, however the AA genotype of MTHFD1 gene G1958A variant associated with increased risk of ovarian cancer. We, also, found that CT and TT genotypes of MTHFR gene C677T variant are associated with altered DNA methylation in ovarian cancer patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by the Shota Rustaveli National Science Foundation of Georgia (grant number #FR-21-17599).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract